Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients

Written by Posted on Less than 0 min read

YANTAI, China, Nov. 15, 2023. RemeGen Co., Ltd. (“RemeGen” or “the Company”), a commercial-stage biotechnology company, is invited to present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session by the American College of Rheumatology(RA). According to the abstract, this Phase III, randomized, double-blind study evaluated the efficacy and safety of telitacicept 160 mg group versus the placebo group in RA patients with inadequate responses to MTX. The study met all its primary endpoints and showed comparable safety profile of telitacicept group vs. control group. Interested parties are welcome to attend Remegen’s presentation session on Wednesday, November 15 from 7:30 a.m. to 9:00 a.m.(PST) at ACR Convergence 2023 at the San Diego Convention Center in California.The invitation to present at ACR Convergence 2023 follows a recent announcement that the Company’s cutting-edge drug telitacicept (RC18) obtained positive results in a Phase III clinical study in the treatment of patients with rheumatoid arthritis in China. Telitacicept is an innovative B-cell lymphocyte stimulator/proliferation inducing ligand(BLyS/APRIL) dual-target fusion protein drug independently developed by RemeGen that can prevent abnormal differentiation of B cells by simultaneously inhibiting the overexpression of two cytokines, BLyS and APRIL, thereby treating a variety of immunology diseases mediated by B cells.

About RemeGen Co. Ltd.

Founded in 2008, RemeGen (9995.HK, SHA: 688331) is a leading biopharmaceutical company in China committed to discovering, developing, and commercializing innovative and differentiated biologic drugs for significant unmet medical needs in the key therapeutic areas including autoimmune, oncology, and ophthalmic diseases. RemeGen has research laboratories and offices throughout China and the United States. For more details, please visit: www.remegen.com

About Telitacicept (RC18)

Telitacicept is RemeGen’s proprietary novel fusion protein for the treatment of autoimmune diseases. It is constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor and the fragment crystallizable (Fc) domain of human immunoglobulin G(IgG). Telitacicept targets two cell-signaling molecules critical for B-lymphocyte development: B-cell lymphocyte stimulator(BLyS) and a proliferation inducing ligand (APRIL), which allows it to effectively reduce B-cell mediated autoimmune responses that are implicated in several autoimmune diseases. It was granted conditional marketing approval by China’s National Medical Products Administration (NMPA) to treat systemic lupus erythematosus (SLE) in March 2021.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to RemeGen, are intended to identify certain of such forward-looking statements. RemeGen does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of RemeGen with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond RemeGen’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, RemeGen’s competitive environment and political, economic, legal and social conditions.

RemeGen, the Directors and the employees of RemeGen assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements do not materialize or turn out to be incorrect.

SOURCE RemeGen Co., Ltd

Posted: November 2023

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Member since

More from Admin

Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic Zoliflodacin to Treat Uncomplicated Gonorrhea

This is the first study to address a World Health Organization priority pathogen that has been sponsored and led by a non-profit organization. These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens. It also paves the way for a new […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy

ROCKVILLE, Md., Nov. 4, 2023. REGENXBIO Inc. today announced additional positive data from the ongoing Phase II ALTITUDE trial of ABBV-RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery. The data will be presented at the American Academy of Ophthalmology meeting in San Francisco, CA by […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

Wegovy (semaglutide) Injection 2.4 mg Cardiovascular Outcomes Data Presented at the American Heart Association Scientific Sessions and Simultaneously Published in the New England Journal of Medicine

PLAINSBORO, N.J., November 11, 2023 – Novo Nordisk today announced the full results of SELECT, its landmark phase 3 cardiovascular outcomes trial investigating the effects of once-weekly Wegovy® (semaglutide) injection 2.4 mg in adults with established cardiovascular disease (CVD) and overweight or obesity but without diabetes, at the American Heart Association (AHA) annual Scientific Sessions […]
Written by
  1. Clinical

AskBio receives FDA Fast Track and MHRA Innovation Passport Designations for AB-1005 Investigational GDNF Gene Therapy for Parkinson’s Disease

Berlin, Germany, and Research Triangle Park, N.C., USA, July 11, 2024 – Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track Designation for AB-1005, which is […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

How domestic rabbits become feral in the wild

Researchers at the Texas A&M School of Veterinary Medicine and Biomedical Sciences (VMBS) have uncovered how natural selection “rewilds” domestic rabbits. The study, published in Nature Ecology and Evolution, helps answer the question of how normally tame rabbits — which have many natural predators — can become a force of ecological destruction when purposefully or […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

‘Robin Hood’ approach for tracking biodiversity

Elise Zipkin and her team at Michigan State University have developed a sort of “Robin Hood” approach to better understand and protect the world’s biodiversity. They’re using information from well-quantified animals to reveal insights about less common, harder-to-observe species. That is, they’re taking insights from the data-rich and giving to the data-poor. Now, they’re sharing […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

Flamingos don’t preen more than other waterbirds

Despite their famously fancy feathers, flamingos don’t spent more time preening than other waterbirds, new research shows. Scientists watched five of the world’s six flamingo species to see how they spend their time. While preening time varied, overall flamingos were roughly average compared to existing studies of other waterbirds. The researchers also examined time spent […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

Rewriting the armadillo family tree: A new species, plus a name change for the state mammal of Texas

While their scaly armor and long claws look vaguely reptilian, armadillos belong to the same group of mammals as sloths and anteaters. There are nearly two dozen species of armadillos, from six-inch long “pink fairies” to giant armadillos that measure five feet long from snout to tail. The nine-banded armadillo has long been considered the […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

Study suggests ‘biodegradable’ teabags don’t readily deteriorate in the environment and can adversely affect terrestrial species

Some teabags manufactured using plastic alternatives do not degrade in soil and have the potential to harm terrestrial species, a new study has shown. The research looked at commonly available teabags made using three different compositions of polylactic acid (PLA), which is derived from sources such as corn starch or sugar cane. The teabags were […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

Brain size riddle solved as humans exceed evolution trend

The largest animals do not have proportionally bigger brains — with humans bucking this trend — a new study published in Nature Ecology and Evolution has revealed. Researchers at the University of Reading and Durham University collected an enormous dataset of brain and body sizes from around 1,500 species to clarify centuries of controversy surrounding […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

The rhythm led by plants is crucial for symbiosis with nutrient-providing bacteria

Legumes thrive in low-nitrogen environments by partnering with rhizobia, soil bacteria that convert atmospheric nitrogen into ammonium, a usable form for the plants. These beneficial bacteria are housed in root nodules formed on legume roots. However, the uncontrolled formation of numerous root nodules can impede root function. To prevent this, legumes need to regulate the […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

Scientists find a region of the mouse gut tightly regulated by the immune system

The intestine maintains a delicate balance in the body, absorbing nutrients and water while maintaining a healthy relationship with the gut microbiome, but this equilibrium is disrupted in parts of the intestine in conditions such as celiac disease, ulcerative colitis, and Crohn’s disease. Scientists don’t fully understand how different regions of the organ resist or […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

Team creates synthetic enzymes to unravel molecular mysteries

A University of Texas at Dallas bioengineer has developed synthetic enzymes that can control the behavior of the signaling protein Vg1, which plays a key role in the development of muscle, bone and blood in vertebrate embryos. The team of researchers is using a new approach, called the Synthetic Processing (SynPro) system, in zebrafish to […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

How do coexisting animals find enough to eat? Biologists unlock insights into foraging habits in Yellowstone

Ecologists have long sought clarity on the dietary habits of different animal species. For scientists at Brown University and the National Park Service, it wasn’t obvious how herbivores in Yellowstone National Park, who subsist on grasses, wildflowers and trees, could compete for enough of those foods to survive the winter. Over two years, with the […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

MicroRNA study sets stage for crop improvements

MicroRNAs can make plants more capable of withstanding drought, salinity, pathogens and more. However, in a recent study published in Nature Plants, Texas A&M AgriLife Research scientists showed just how much we didn’t know about the intricate processes plants use to produce them. MicroRNAs are small molecules that can guide proteins to decrease gene expression, […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

FDA Approves Arcutis’ Zoryve (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Zoryve (roflumilast) cream, 0.15%, for the treatment of mild to moderate atopic […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

U.S. Meals and Drug Administration (FDA) Has Accepted the New Drug Software (NDA) for Ensartinib

Therapy for: Non-Small Cell Lung Most cancers U.S. Meals and Drug Administration (FDA) Has Accepted the New Drug Software (NDA) for Ensartinib MIAMI–(BUSINESS WIRE) March 13, 2024 –Xcovery Holdings, Inc., an oncology centered pharmaceutical firm, as we speak introduced that the U.S. Meals and Drug Administration (FDA) has accepted the New Drug Software (NDA) for […]
Written by
  1. Biology

Young male northern elephant seals are captured on camera returning to a

Young male northern elephant seals are captured on camera returning to a deep sea cabled observatory off Canada’s British Columbia coast, demonstrating new insight into fish foraging behavior Credit: Ocean Networks Canada, CC-BY 4.0 ( Young male northern elephant seals are captured on camera returning to a deep sea cabled observatory off Canada’s British Columbia […]
Written by
Next
No Comments
Leave a comment Cancel
Comments to: Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.